US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Stage

0.3754

0.0000

Volume:- -

Turnover:- -

Market Cap:10.85M

PE:-0.11

High:0.3754

Open:0.3754

Low:0.3754

Close:0.3754

52wk High:9.50

52wk Low:0.2700

Shares:28.91M

Float Shares:20.31M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.05

Dividend Rate:13.32%

EPS(TTM):-3.3321

EPS(LYR):-3.1264

ROE:-44.60%

ROA:-3.54%

PB:0.07

PE(LYR):-0.12

Loading ...

Overview Company News Filings

Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability

Copper Giant Advances PEA-Stage Metallurgical Work at Mocoa Project

Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial -- Update

Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction

MT Newswires Live

Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts

Shrewsbury International School Hong Kong Launches Key Stage 3, Establishing Seamless Pathways to Global Excellence

Assessing Tuya (TUYA) Valuation As Earnings Expectations And Guidance Take Center Stage

Simply Wall St.

Viridian Therapeutics: Well-Funded Late-Stage Pipeline and Imminent Phase 3 Catalysts Support Buy Rating and $42 Target

Nippon Shinyaku’s NS-863 PAH Trial: Early-Stage Catalyst in a Competitive Specialty Market

Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward

Lumen Turnaround Sets Stage For Fiber Growth And AI Network Shift

Simply Wall St.

Xenon Highlights 2025 Results and Expands Late-Stage Pipeline

Argentina's Reforms Set the Stage for the Return of Its Bond Market -- Barrons.com

Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target

Geron: Early-Stage Rytelo Demand and Disciplined Investment Support Multi‑Year Growth and 2026 Reacceleration

Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts

Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating

Delta-Fly Pharma Discontinues Late-Stage AML Study

MT Newswires Live

BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation

eWeLL Tops FY2025 Forecasts and Sets Stage for New Medium-Term Growth Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SSI/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","market":"US","secType":"STK","nameCN":"Stage","latestPrice":0.3754,"timestamp":1588968000000,"preClose":0.3754,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":20307519,"shares":28911336,"eps":-3.332056,"marketStatus":"Halted","change":0,"latestTime":"05-08 16:00:00 EDT","open":0.3754,"high":0.3754,"low":0.3754,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.332056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":998884800000,"exchange":"NYSE","adjPreClose":0.3754,"dividendRate":0.133191,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"SSI\",,,,,undefined,":{"symbol":"SSI","floatShares":20307519,"roa":"-3.54%","roe":"-44.60%","lyrEps":-3.1264,"shares":28911336,"dividePrice":0.05,"high":0.3754,"amplitude":0,"preClose":0.3754,"low":0.3754,"week52Low":0.27,"pbRate":"0.07","week52High":9.5,"institutionHeld":0.5253,"latestPrice":0.3754,"eps":-3.332056,"divideRate":0.133191,"volume":0,"delay":0,"ttmEps":-3.332056,"open":0.3754,"prevYearClose":8.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-21","symbol":"SSI","fiscalQuarterEnding":"2019/10","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1574312400000,"reportTimeType":"pre","actualEps":-0.15},{"date":"2019-08-22","symbol":"SSI","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/07","expectedEps":null,"defaultRemindTime":1566460800000,"name":null,"time":"Pre-Market","dateTimestamp":1566446400000,"actualEps":-0.6},{"market":"US","date":"2019-05-23","symbol":"SSI","fiscalQuarterEnding":"2019/04","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1558584000000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2019-03-07","symbol":"SSI","fiscalQuarterEnding":"2019/01","expectedEps":0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"pre","actualEps":0.25},{"market":"US","date":"2018-12-03","symbol":"SSI","amount":0.05,"name":"Stage Stores Inc","currency":"USD","type":"dividend","dateTimestamp":1543813200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSI\",market:\"US\",,,undefined,":[{"executeDate":"2017-02-24","recordDate":null,"paymentDate":null,"value":0.15,"currency":"USD"},{"executeDate":"2017-05-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-08-25","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2017-11-27","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"},{"executeDate":"2018-03-05","recordDate":null,"paymentDate":null,"value":0.05,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSI\",market:\"US\",delay:true,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSI\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616313418","title":"Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2616313418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616313418?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:00","pubTimestamp":1772517636,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics, Inc. (APGE) has disclosed a new risk, in the Share Price & Shareholder Rights category. An external analyst notes that investi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-stock-clinical-stage-risks-unproven-pipeline-and-uncertain-path-to-profitability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apogee-therapeutics-stock-clinical-stage-risks-unproven-pipeline-and-uncertain-path-to-profitability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","BK4139","APGE","LU0053671581.USD"],"gpt_icon":0},{"id":"2616284356","title":"Copper Giant Advances PEA-Stage Metallurgical Work at Mocoa Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2616284356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616284356?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:08","pubTimestamp":1772464137,"startTime":"0","endTime":"0","summary":"Libero Copper & Gold ( ($TSE:CGNT) ) has shared an update. Copper Giant Resources has launched the next phase of metallurgical testing at its Mocoa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/copper-giant-advances-pea-stage-metallurgical-work-at-mocoa-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/copper-giant-advances-pea-stage-metallurgical-work-at-mocoa-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGUmain","GDX","GCmain","DUST","BK4535","COPX","SSI","159934","HGmain","SGCmain","IAU","NUGT","MGCmain","BK4585","518880","BK4588"],"gpt_icon":0},{"id":"2616323337","title":"Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323337","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323337?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:08","pubTimestamp":1772456880,"startTime":"0","endTime":"0","summary":"Roche Holding said a drug candidate for multiple sclerosis met the primary goal in a late-stage clinical trial for the most common form of the disease.The Swiss pharmaceutical company said Monday that the drug, called fenebrutinib, led to a reduction in the annualized rate of relapses--when symptoms get worse--in patients with relapsing multiple sclerosis. The company said it would submit results from this and a prior study, together with a third trial in a less common form of the disease, to regulatory authorities.Roche currently has in another multiple-sclerosis drug, Ocrevus, its top-selling product that generated just over 7 billion Swiss francs  in sales last year.With fenebrutinib, the company is aiming to launch a new oral treatment for the disease that offers both greater convenience to patients relative to Ocrevus, which is available as an intravenous infusion and a subcutaneous injection, and more efficacy than other tablets.While fenebrutinib showed efficacy in the trials, s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RHHBY","SSI","03165"],"gpt_icon":0},{"id":"2616339393","title":"Rhythm Says New Late-Stage Data for Obesity Drug Shows Strong Weight Loss, Hunger Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339393","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339393?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:44","pubTimestamp":1772451899,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals  on Sunday shared new results from a late-stage trial of its drug setmelanotide for acquired hypothalamic obesity, a rare condition that causes extreme weight gain and hunger.The data showed that after 52 weeks, patients taking the drug saw their body mass index  drop by 16.4% on average. At the same time, patients on placebo saw their BMI rise by 2.4%.The drug also reduced hunger, the company said. Patients aged 12 and older reported a 2.5-point drop in weekly hunger scores, compared with a 1.3-point drop in the placebo group, it said.The new data includes additional patients from Japan, and others added beyond the main study group, according to the company.The US FDA is reviewing the drug, with a Prescription Drug User Fee Act decision expected by March 20, Rhythm said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BMI","SSI","BK4585","RYTM","BK4588","BK4157","BK4139"],"gpt_icon":0},{"id":"2616336047","title":"Celldex: Barzolvolimab’s Durable Efficacy in Chronic Urticaria Underpins Buy Rating Ahead of Key Late-Stage Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2616336047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616336047?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:36","pubTimestamp":1772451402,"startTime":"0","endTime":"0","summary":"Celldex, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/celldex-barzolvolimabs-durable-efficacy-in-chronic-urticaria-underpins-buy-rating-ahead-of-key-late-stage-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/celldex-barzolvolimabs-durable-efficacy-in-chronic-urticaria-underpins-buy-rating-ahead-of-key-late-stage-catalysts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2616388683","title":"Shrewsbury International School Hong Kong Launches Key Stage 3, Establishing Seamless Pathways to Global Excellence","url":"https://stock-news.laohu8.com/highlight/detail?id=2616388683","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616388683?lang=en_us&edition=fundamental","pubTime":"2026-03-02 18:00","pubTimestamp":1772445600,"startTime":"0","endTime":"0","summary":"HONG KONG, March 2, 2026 /PRNewswire/ -- Shrewsbury International School Hong Kong is pleased to announce the launch of its Key Stage 3 programme, welcoming Year 7 students starting August 2026, with Year 8 to follow in August 2027. This strategic expansion transforms Shrewsbury Hong Kong into a through-train school, providing a seamless educational experience from Early Years through Year 8 and beyond, all within the esteemed Shrewsbury family.Global Vision: Fostering Future-Ready Leaders. Shrewsbury Hong Kong Principal, Priya Kanthan, with a group of students.The new Key Stage 3 programme is meticulously designed to cultivate leadership qualities and a global mindset among our students. Our holistic curriculum emphasises critical thinking, creativity, and global citizenship, nurturing a diverse community that honors Hong Kong's rich cultural heritage. \"The expansion into Key Stage 3 is a natural evolution of our mission to nurture curious, confident, and capable global citizens,\" sta","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2920135/Shrewsbury_Hong_Kong_Principal_Priya_Kanthan_a_group_students.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2920135/Shrewsbury_Hong_Kong_Principal_Priya_Kanthan_a_group_students.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/shrewsbury-international-school-hong-kong-launches-key-stage-3-establishing-seamless-pathways-to-global-excellence-302700474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI"],"gpt_icon":0},{"id":"2616300821","title":"Assessing Tuya (TUYA) Valuation As Earnings Expectations And Guidance Take Center Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2616300821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616300821?lang=en_us&edition=fundamental","pubTime":"2026-03-01 16:17","pubTimestamp":1772353074,"startTime":"0","endTime":"0","summary":"Tuya (TUYA) is in focus ahead of its March 2, 2026 quarterly earnings release, as investors watch to see whether the company can meet expectations for $0.03 in earnings per share and provide guidance that supports its outlook.\nSee our latest analysis for Tuya.\nAt a share price of $2.55, Tuya has seen strong near term momentum, with a 1 day share price return of 5.37% and a 30 day share price return of 22.01%. However, its 1 year total shareholder return of 22.17% and 3 year total shareholder...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice1-main-header/1585186668959"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nyse-tuya/tuya/news/assessing-tuya-tuya-valuation-as-earnings-expectations-and-g","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nyse-tuya/tuya/news/assessing-tuya-tuya-valuation-as-earnings-expectations-and-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SSI","TUYA"],"gpt_icon":0},{"id":"2614319864","title":"Viridian Therapeutics: Well-Funded Late-Stage Pipeline and Imminent Phase 3 Catalysts Support Buy Rating and $42 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2614319864","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614319864?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:55","pubTimestamp":1772222124,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger has maintained their bullish stance on VRDN stock, giving a Buy rating today. Serge Belanger has given his Buy ratin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/viridian-therapeutics-well-funded-late-stage-pipeline-and-imminent-phase-3-catalysts-support-buy-rating-and-42-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/viridian-therapeutics-well-funded-late-stage-pipeline-and-imminent-phase-3-catalysts-support-buy-rating-and-42-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SSI"],"gpt_icon":0},{"id":"2614194863","title":"Nippon Shinyaku’s NS-863 PAH Trial: Early-Stage Catalyst in a Competitive Specialty Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2614194863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614194863?lang=en_us&edition=fundamental","pubTime":"2026-02-28 00:37","pubTimestamp":1772210244,"startTime":"0","endTime":"0","summary":"Nippon Shinyaku Co., Ltd. ($JP:4516) announced an update on their ongoing clinical study. The Phase 2 trial “A Phase 2, Randomized, Double-Blind, P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nippon-shinyakus-ns-863-pah-trial-early-stage-catalyst-in-a-competitive-specialty-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nippon-shinyakus-ns-863-pah-trial-early-stage-catalyst-in-a-competitive-specialty-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2614875518","title":"Definium Therapeutics: Late-Stage Pipeline Progress and Upcoming Phase 3 Readouts Support Buy Rating and Favorable Risk-Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2614875518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614875518?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:45","pubTimestamp":1772178357,"startTime":"0","endTime":"0","summary":"Definium Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham reiterated a Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/definium-therapeutics-late-stage-pipeline-progress-and-upcoming-phase-3-readouts-support-buy-rating-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","DFTX","PRGS"],"gpt_icon":0},{"id":"2614833001","title":"Lumen Turnaround Sets Stage For Fiber Growth And AI Network Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833001","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614833001?lang=en_us&edition=fundamental","pubTime":"2026-02-27 09:27","pubTimestamp":1772155624,"startTime":"0","endTime":"0","summary":"Lumen Technologies (NYSE:LUMN) has announced the completion of its business turnaround.\nThe company outlined a multi year growth plan centered on fiber expansion and AI driven enterprise services.\nLumen is adopting Blue Planet AI agents to overhaul how its network is monitored and managed.\n\nLumen Technologies, trading at $7.04, is highlighting a shift from its legacy telecom roots toward an enterprise focused, AI enabled infrastructure model. The share price has seen a 56.1% return over the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/260149-main-header/1585187100893","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/260149-main-header/1585187100893"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/telecom/nyse-lumn/lumen-technologies/news/lumen-turnaround-sets-stage-for-fiber-growth-and-ai-network","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/telecom/nyse-lumn/lumen-technologies/news/lumen-turnaround-sets-stage-for-fiber-growth-and-ai-network","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535","BK4554","SSI","AIYY","LUMN","BK4588","BK4023","LU0149725797.USD","BK4528","BK4543","BK4089","BK4585","BK4587","BK4551"],"gpt_icon":1},{"id":"2614681074","title":"Xenon Highlights 2025 Results and Expands Late-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2614681074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614681074?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:52","pubTimestamp":1772142744,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Xenon ( ($XENE) ). On Feb. 26, 2026, Xenon Pharmaceuticals reported its fourth-quarter and full-year 2025 resul...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-highlights-2025-results-and-expands-late-stage-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-highlights-2025-results-and-expands-late-stage-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2614023438","title":"Argentina's Reforms Set the Stage for the Return of Its Bond Market -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2614023438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614023438?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:58","pubTimestamp":1772117880,"startTime":"0","endTime":"0","summary":"Argentine President Javier Milei hasn't wielded a chain saw at any U.S. political conventions lately. He has better things to do.The hirsute libertarian, using leverage from his midterm elections triumph in October, just massaged labor reform legislation through Congress, delivering one of the Big Three structural reforms on markets' wish list. Argentine bonds keep creeping up in value. Investors expect the serial defaulting nation to come back to markets this year.\"We would be interested as long as the price makes sense,\" says Thierry Larose, portfolio manager for emerging markets local debt at Vontobel Asset Management.That is a remarkable turnaround since Milei took power 27 months ago with an economy near hyperinflation and a treasury headed for another bankruptcy. It's also way too early for him to declare Mission Accomplished.The labor legislation is \"a big deal,\" says Benjamin Gedan, director of the Latin America program at the Stimson Center. \"Now you get the feeling that this ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SSI","US3Y.BOND","US12M.BOND","US7Y.BOND","TMF","US2Y.BOND","US30Y.BOND","US6M.BOND","US5Y.BOND","US10Y.BOND","TLTW"],"gpt_icon":1},{"id":"2614062249","title":"Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2614062249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614062249?lang=en_us&edition=fundamental","pubTime":"2026-02-26 10:55","pubTimestamp":1772074521,"startTime":"0","endTime":"0","summary":"Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Protagonist Therapeutics, with a price target of $100.00. Tara Bancroft has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/protagonist-therapeutics-late-stage-pipeline-strength-and-rusfertide-economics-drive-buy-rating-and-100-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/protagonist-therapeutics-late-stage-pipeline-strength-and-rusfertide-economics-drive-buy-rating-and-100-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","SSI"],"gpt_icon":0},{"id":"2614032516","title":"Geron: Early-Stage Rytelo Demand and Disciplined Investment Support Multi‑Year Growth and 2026 Reacceleration","url":"https://stock-news.laohu8.com/highlight/detail?id=2614032516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614032516?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:15","pubTimestamp":1772039747,"startTime":"0","endTime":"0","summary":"Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Geron. The associated price target remains the same with $3.00. Tara Bancroft...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/geron-early-stage-rytelo-demand-and-disciplined-investment-support-multi‑year-growth-and-2026-reacceleration-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/geron-early-stage-rytelo-demand-and-disciplined-investment-support-multi‑year-growth-and-2026-reacceleration-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GERN","SSI","BK4139"],"gpt_icon":0},{"id":"2614703447","title":"Balanced Hold on United Therapeutics Amid Near-Term Pressure and Key Late-Stage Pipeline Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2614703447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614703447?lang=en_us&edition=fundamental","pubTime":"2026-02-26 00:45","pubTimestamp":1772037936,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn maintained a Hold rating on United Therapeutics today and set a price target of $447.00. Terence Flynn has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-hold-on-united-therapeutics-amid-near-term-pressure-and-key-late-stage-pipeline-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-hold-on-united-therapeutics-amid-near-term-pressure-and-key-late-stage-pipeline-readouts-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0098860793.USD","LU0912757837.SGD","LU1244550577.SGD","LU1699723380.USD","LU1668664300.SGD","BK4585","BK4504","LU2111349929.HKD","LU0795875169.SGD","LU2089283258.USD","LU1720051108.HKD","UTHR","BK4534","BK4532","LU1732799900.SGD","LU1989772840.SGD","LU1571399168.USD","BK4139","LU1162221912.USD","LU1791710400.SGD","BK4127","LU1244550221.USD","LU1244550494.USD","IE00BZ1G4Q59.USD","LU1989772923.USD","LU1791710582.SGD","LU2028103732.USD","BK4516","LU2023251221.USD","LU1363072403.SGD","SSI","LU0528227936.USD","LU0267386448.USD","LU1720051017.SGD","IE00BKVL7J92.USD","LU2347655156.SGD","LU1074936037.SGD","LU0314104364.USD","LU0320765646.SGD","LU2089284900.SGD","BK4581","LU1548497426.USD","LU2133065610.SGD","LU0225283273.USD","LU2271345857.HKD","LU0106261372.USD","LU0557290698.USD","LU1732800096.USD","LU0158827781.USD"],"gpt_icon":0},{"id":"2614086204","title":"Evolent Health: Conservative Guidance and Elevated Reserves Set the Stage for 2026 Margin Upside and Support a Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614086204","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614086204?lang=en_us&edition=fundamental","pubTime":"2026-02-25 19:35","pubTimestamp":1772019348,"startTime":"0","endTime":"0","summary":"In a report released yesterday, David Larsen from BTIG maintained a Buy rating on Evolent Health, with a price target of $8.00. David Larsen has gi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/evolent-health-conservative-guidance-and-elevated-reserves-set-the-stage-for-2026-margin-upside-and-support-a-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/evolent-health-conservative-guidance-and-elevated-reserves-set-the-stage-for-2026-margin-upside-and-support-a-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EVH","SSI"],"gpt_icon":0},{"id":"2614570178","title":"Delta-Fly Pharma Discontinues Late-Stage AML Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2614570178","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614570178?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:50","pubTimestamp":1772009400,"startTime":"0","endTime":"0","summary":"Delta-Fly Pharma  discontinued a U.S. Phase 3 trial of DFP-10917 in relapsed or refractory acute myeloid leukemia after an interim analysis failed to show superiority over control treatment.The Data Safety Monitoring Board made a go/no-go decision based on interim data in patients receiving third-line or later therapy, according to a Wednesday filing on the Tokyo Stock Exchange.While there was no statistically significant difference in overall response rate or overall survival versus the control group, the company said DFP-10917 showed a higher response rate overall and longer survival than intensive chemotherapy in certain comparisons.The drug also showed efficacy in a subset of poor-prognosis patients resistant to conventional therapies.DFP-10917 has orphan drug designation from the U.S. Food and Drug Administration. Delta-Fly Pharma plans to discuss the possibility of conditional new drug application approval with the agency.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI"],"gpt_icon":0},{"id":"2614709941","title":"BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2614709941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614709941?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:15","pubTimestamp":1772007324,"startTime":"0","endTime":"0","summary":"Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on BridgeBio Pharma. The associated price target remains the same with $95.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bridgebio-robust-attruby-launch-and-late-stage-pipeline-support-buy-rating-and-path-to-sustainable-cash-generation-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bridgebio-robust-attruby-launch-and-late-stage-pipeline-support-buy-rating-and-path-to-sustainable-cash-generation-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0},{"id":"2614712347","title":"eWeLL Tops FY2025 Forecasts and Sets Stage for New Medium-Term Growth Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2614712347","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614712347?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:24","pubTimestamp":1771993489,"startTime":"0","endTime":"0","summary":"eWeLL Co.,Ltd ( ($JP:5038) ) has provided an update. eWeLL Co., Ltd. reported strong FY12/2025 results, with net sales rising 31.9% year on year to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ewell-tops-fy2025-forecasts-and-sets-stage-for-new-medium-term-growth-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ewell-tops-fy2025-forecasts-and-sets-stage-for-new-medium-term-growth-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}